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dopaminergic pathway such as the dopamine trans-
Monoamine oxidase (MAO), which exists in two porter (9,10), the dopamine receptor D2 (11,12), the
forms (MAOA and MAOB), plays an important role in dopamine receptor D4 (13,14), the degradative enzyme
the oxidative metabolism of neurotransmitters such as catechol-O-methyltransferase (15,16) and the mono-
dopamine, and has been implicated in the etiology of amine oxidase (MAO) (17-25) may be involved in theParkinson's disease (PD). Individual variations in the
disease process. In particular, the primary enzymeactivity of these enzymes appear to be genetically de-
MAO for the degradation of neurotransmitters such astermined, and these genetic variations appear to be
dopamine, noradrenaline, and serotonin is thought topredominantly mediated by the MAO locus. Here, we
be associated with the susceptibility of individuals todetected and analyzed four polymorphic markers in
PD. The enzyme exists in two forms, MAOA andthe MAO gene using a polymerase chain reaction
MAOB, which can be distinguished on the basis of theirmethod in 228 Japanese controls (102 males and 126
differences in pharmacologic and biochemical charac-females) and 68 patients with PD (30 males and 38 fe-
teristics. The genes for both forms of MAO are locatedmales). Although the analysis of the MAOA marker
demonstrated no overall association between its al- in the same (p11.23-11.4) region of the human X chro-
leles and PD, a signi®cant difference in the frequency mosome (26). Individual variations in activity of these
of one particular MAOA allele between controls and enzymes appear to be genetically determined, and
patients with PD was found. Moreover, in a compari- these genetic variations appear to be predominantly
son of the distribution of the full haplotypes at the mediated by the MAO locus (27).
MAOA locus, there was a signi®cant difference in the To date, several expressed polymorphisms in the
frequency of one particular haplotype between male MAO gene have been identi®ed and characterized, and
controls and patients with PD. In the MAOB polymor- four of them are as follows; i) a (GT)n dinucleotide re-
phism, there was no difference in the distribution of peat in intron 2 of the MAOA gene (MAOA-GT) (17),
alleles between them. These ®ndings support the hy- ii) the imperfectly duplicated 23-bp VNTR in intron 1pothesis that the MAOA gene may affect the suscepti-
of the MAOA gene (MAOA-VNTR) (24), iii) an Fnu4HI-bility of individuals to PD among MAOA polymorphic
RFLP in exon 8 of the MAOA gene (MAOA-RFLP) (25),loci. q 1998 Academic Press
and iv) a (GT)n dinucleotide repeat in intron 2 of the
MAOB gene (MAOB-GT) (18). Several association stud-
ies between these polymorphisms and PD have been
Parkinson's disease (PD) is a neurodegenerative dis- performed, and a recent study found a signi®cant dif-
order caused by death of dopaminergic neurons in the ference in the frequency of MAOA haplotypes in male
substantia nigra, and the symptoms are thought to oc- patients with PD compared with normal controls (22).
cur with alterations of the dopamine levels in the stria- However, whether these polymorphisms at MAO are
tum (1). Over the last decade, the role of genetic and directly involved in individual differences in suscepti-
environmental factors in the etiology of PD has been bility to PD have not yet been determined.
the subject of controversy (2-8). Recent studies have To clarify the potential implication in the pathogene-
suggested that several genes encoding proteins of the sis of PD, we detected and analyzed the four identi®ed
polymorphisms in the MAO gene, and subsequently
assessed the frequency of alleles for MAOA and MAOB1 To whom correspondence should be addressed. Fax: 81-6-879-
in Japanese controls and patients with PD. Further-3119. E-mail: nakatome@legal.med.osaka-u.ac.jp
Abbreviations: MAO, monoamine oxidase; PD, Parkinson's disease. more, we assessed the haplotype frequencies of MAOA
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TABLE 1
Primer Sequences and PCR Thermal Conditions
Primer name [Ref. No.] Sequence (5*±3 *) Denaturation Annealing Extension Cycles
MAOA-GT 1 [17] HEX-AGAGACTAGACAAGTTGCAC 947C 607C 727C 30
MAOA-GT 2 [17] CACTATCTTGTTAGCTCACT 30 sec. 45 sec. 60 sec.
MAOA-VNTR 1 [24] GGTAGACTCCTTTAAGAAAA 957C 537C 727C 30
MAOA-VNTR 2 [24] CAATAAATGTCCTACACCTT 30 sec. 40 sec. 40 sec.
MAOA-RFLP 1 [25] GACCTTGACTGCCAAGAT 957C 577C 727C 30
MAOA-RFLP 2 [25] CTTCTTCTTCCAGAAGGCC 30 sec. 45 sec. 60 sec.
MAOB-GT 1 [18] 6-FAM-GAAGCATCGAAGTTAGGA 957C 607C 727C 30
MAOB-GT 2 [18] GTATTTGGCCTCATAGAGTTAG 30 sec. 30 sec. 60 sec.
in male controls and patients with PD since males pos- RESULTS
sess only one allele (on the X chromosome) which en-
Allele frequencies for each of the three MAOA mark-ables direct determination of the haplotype.
ers in controls and patients with PD are shown in Table
2. Analysis of the MAOA marker demonstrated no over-MATERIALS AND METHODS
all association between alleles and PD (MAOA-GT:To-
tal; x2 13.02, df8, p0.11. Male; x2 12.58, df7,Patients and controls. After obtaining informed consent, 68 unre-
p0.08. Female; x212.67, df8, p0.12., MAOA-lated Japanese patients with PD (38 males and 30 females, 48-90
VNTR:Total; x2 1.17, df2, p0.59. Male; x22.57,years of age) were selected from Osaka University Medical Hospital.
All patients met the diagnostic criteria for idiopathic PD. The control df2, p0.28. Female; x2 2.68, df2, p0.99.,
group consisted of 228 unrelated Japanese individuals (102 males MAOA-RFLP:Total, Male and Female; p0.99.). How-
and 126 females, 20-60 years of age). All controls were free of neuro- ever, further analysis of each allele separately usinglogic and psychiatric illness.
Fisher's exact test demonstrated a signi®cant deviation
DNA extraction. Genomic DNA was extracted from the whole in the MAOA-GT allele ``119'' (Total; x210.02, df1,blood (28). After incubation with proteinase K (125 mg/ml) in lysis
p0.004. Male; x27.33, df1, p0.019. Female;buffer (3 ml containing 50 mM Tris-HCl, 100 mM NaCl, 0.5% SDS,
x26.50, df1, p0.025. See Table 2.) between controls1 mM EDTA) at 557C for 3 hours, protein contaminants were removed
by phenol/chloroform extraction, precipitated with ethanol, and then and patients with PD. This difference reached the sig-
dried and stored at 0207C in 10 mM Tris-HCl (pH 7.6). Extracted ni®cant level after Bonferroni's correction in total (nine
DNA was quanti®ed by measuring the optical density at 260 nm; a alleles, critical P value  0.0056). The incidence of al-value of 1.0 was regarded to correspond to 50 mg/ml DNA.
lele 119 was almost three, ten and 2.5 times more fre-
DNA ampli®cation by polymerase chain reaction. DNA ampli®- quent in patients with PD than controls in total, males
cation was performed using a Parkin-Elmer GeneAmp System 2400
and females, respectively.in a total volume of 25 ml reaction mixtures containing 50 ng genomic
Table 3 shows the distribution of haplotypic combi-DNA(template), 200 mM each of dATP, dTTP, and dCTP, 100 mM
dGTP, 0.5 mM of each primer, 2.5 units of Taq DNA polymerase nations at the MAOA locus in male controls and pa-
(Promega), and 1.5 mM MgCl2. The oligonucleotide primers and PCR tients with PD. In a comparison of the distribution of
thermal conditions are shown in Table 1. Since MAOA-GT and the full haplotypes [(GT)n/VNTR/RFLP] at theMAOB-GT consist of short tandem repeat polymorphisms, a ¯uores-
MAOA locus, there was a signi®cant difference in thecently labeled primer was used for PCR.
frequency of haplotype ``119-C-R2'' between controls
Laboratory genotyping. In MAOA-GT and MAOB-GT, PCR prod- and patients with PD (x2  11.05, df1, p0.005).ucts were electrophoresed on a 6% denatured polyacrylamide gel in a
However, the overall distribution of these haplo-Parkin-Elmer 373A DNA sequencer. Sizing and designation of alleles
were performed using both the internal lane standard GeneScan types was not signi®cantly different between them
Tamra 500 and ABI PRISM 672 analysis software. (x221.55, df24, p0.61).
The MAOA-VNTR products and the Fun4HI-digested products
were electrophoresed for 3 hours at 150V in 2.0% GTG agarose gel
(FMC Bio Products) and 3.0% Metaphor agarose gel (FMC Bio Prod-
ucts), respectively, and directly visualized with ethidium bromide
under UV illumination. Each band size was calculated with the loga-
rithmic regression curve determined by mobility of the standard size
marker (100 base pair ladder; Parmacia-LKB).
The genomic organization of these genes and the relative position
of the polymorphisms are shown in Figure 1.
Statistical analysis. Statistical analysis was performed by the
Chi-square test and Fisher's exact test (29) to compare the allelic FIG. 1. Genomic organization (not in scale) of the human MAO
genes. The relative position of the MAO polymorphisms are indicatedfrequencies of MAOA and MAOB alleles in patients with PD and the
control group. (30).
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TABLE 2
Distribution of Alleles at the MAOA Locus in Controls and Patients with Parkinson's Disease
Total Male Female
Control (N  228) Patients (N  68) Control (N  102) Patients (N  38) Control (N  126) Patients (N  30)
Allele n n n n n n
MAOA-GT
113 9 (2.5) 3 (3.1) 3 (2.9) 0 (0) 6 (2.4) 3 (5.0)
115 85 (24.0) 20 (20.4) 21 (20.6) 8 (21.1) 64 (25.4) 12 (20.0)
117 63 (17.8) 17 (17.3) 13 (12.7) 8 (21.1) 50 (19.8) 9 (15.0)
119 20 (5.6) 15 (15.3)* 1 (1.0) 4 (10.5)** 19 (7.5) 11 (18.3)***
121 28 (7.9) 8 (8.2) 13 (12.7) 2 (5.3) 15 (6.0) 6 (10.0)
123 96 (27.1) 25 (25.5) 37 (36.3) 10 (26.3) 59 (23.4) 15 (25.0)
125 42 (11.9) 8 (8.2) 9 (8.8) 5 (13.2) 33 (13.1) 3 (5.0)
127 9 (2.5) 2 (2.0) 5 (4.9) 1 (2.6) 4 (1.6) 1 (1.7)
129 2 (0.6) 0 (0) 0 (0) 0 (0) 2 (0.8) 0 (0)
MAOA-VNTR
A 12 (3.4) 2 (2.0) 8 (7.8) 1 (2.6) 4 (1.6) 1 (1.7)
B 212 (59.9) 55 (56.1) 56 (54.9) 18 (47.4) 156 (62.0) 37 (61.7)
C 130 (36.7) 41 (41.8) 38 (37.3) 19 (50.0) 92 (36.5) 22 (36.7)
MAOA-RFLP
R1 209 (59.0) 58 (59.2) 58 (56.9) 20 (52.6) 151 (59.9) 38 (63.3)
R2 145 (41.0) 40 (40.8) 44 (43.1) 18 (47.4) 101 (40.1) 22 (36.7)
Note. Number in parentheses indicates percentage. N: number of individuals; n: number of X chromosomes analyzed.
*: x2  10.02, df  1, p  0.004. **: x2  7.33, df  1, p  0.019. ***: x2  6.50, df  1, p  0.025. (Fisher's exact test.)
There was no difference in the distribution of MAOB GT in the frequency of each allele, although both differ-
ences did not reach the signi®cant level after Bonfer-alleles between controls and patients with PD as shown
roni's correction. They detected a total of nine allelesin Table 4.
(from A1 to A9) in the Japanese population in MAOA-
GT but the sizes of the alleles were not described.
Therefore, we could not directly compare our JapaneseDISCUSSION data with theirs. However, as the A4 allele of MAOA
that they reported is the same as the ``119'' allele that
The purpose of this study was to demonstrate we reported here, susceptibility of individuals to PD
whether MAO polymorphisms are directly involved in mediated by the levels of MAOA activity may be associ-
individual differences in susceptibility to PD. MAO ated with the MAOA-GT ``119'' allele in Japanese. On
plays an important role in metabolizing several neuro- the other hand, we did not ®nd an association between
transmitters such as dopamine, and exhibits more than PD and alleles of MAOB-GT because our investigation
50-fold variations in activity levels among normal hu- was performed in a larger sample size than their inves-
mans (30,31). In view of this trait, we hypothesized tigation. They detected a total of eight alleles in 211
that MAO polymorphisms may affect some gene ex- chromosomes in MAOB-GT, compared to twelve alleles
pression in forms of various haplotypic combinations in 393 chromosomes in the present study.
among MAO polymorphic loci, thus resulting in wide Meanwhile, Kurth et al. (6) reported that no allelic
variations in activity in humans. association between patients and controls for MAOA-
The result of the experiment was that we found sig- RFLP was found in the mixed European white popula-
ni®cant differences between controls and patients with tion. This ®nding are in agreement with our Japanese
PD in the MAOA-GT allele ``119'' and MAOA haplotype data. At the same time, they found a signi®cant associ-
``119-C-R2''. However, regarding the MAOB gene, we ation between a MAOB polymorphism de®ned by a sin-
found no such difference. gle-strand conformation polymorphism and PD al-
Previously, Nanko et al. (20) reported that signi®cant though Ho et al. (7) failed to ®nd any association be-
associations were found between PD and allele A4 of tween them. After a while, Morimoto et al. (21)
investigated this MAOB polymorphism in the JapaneseMAOA-GT, and between PD and allele B4 of MAOB-
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TABLE 3 ence in the MAOB allelic frequency between the Japa-
nese and Caucasian populations, suggesting that envi-Distribution of Haplotypic Combinations at the MAOA
Locus in Male Controls and Patients with Parkinson's ronmental factors may play some roles in the preven-
Disease tion of PD in Japanese with genetic susceptibility for
PD. We also support their idea that environmental fac-
Controls (n  102) Patients (n  38) tors may be involved in the development of PD since
Haplotypes n (%) n (%) many discordant results have been reported with re-
gard to MAO polymorphisms.113-C-R1 3 (2.9) 0 (0)
In other previous studies, PlanteÂ-Bordeneuve et al.115-B-R1 2 (2.0) 1 (2.6)
115-C-R1 15 (14.7) 5 (13.2) (8) reported that no allelic association was found be-
115-C-R2 4 (3.9) 2 (5.3) tween MAOA-GT, MAOB-GT and sporadic PD in the
117-B-R2 1 (1.0) 1 (2.6) mixed European white population. On the contrary,117-C-R1 9 (8.8) 5 (13.2)
Hotamisligil et al. (22) reported that the haplotype117-C-R2 3 (2.9) 2 (5.3)
``C122'' was markedly different in the frequency of119-B-R2 1 (1.0) 0 (0)
119-C-R2 0 (0) 4 (10.5)* MAOA haplotypes between controls and patients with
121-A-R2 1 (1.0) 0 (0) PD, and Hsu et al. (23) suggested that since this ``C122''
121-B-R1 5 (4.9) 1 (2.6) allele which is associated with high activities of MAOA121-B-R2 6 (5.9) 1 (2.6)
occurred less frequently among patients with PD than121-C-R2 1 (1.0) 0 (0)
among controls, low levels of MAOA activity may be123-A-R1 1 (1.0) 0 (0)
123-A-R2 4 (3.9) 1 (2.6) implicated in the susceptibility of individuals to PD in
123-B-R1 15 (14.7) 4 (10.5) some patients. In Japanese, the frequency of ``122'' al-
123-B-R2 14 (13.7) 4 (10.5) lele of MAOA was not different between patients and123-C-R1 1 (1.0) 1 (2.6)
controls. However, taking the ethnic difference into123-C-R2 2 (2.0) 0 (0)
consideration, the ``119'' allele (especially MAOA haplo-125-A-R1 1 (1.0) 0 (0)
125-A-R2 1 (1.0) 0 (0) type ``119-C-R2'') that we reported here may be in-
125-B-R1 3 (2.9) 3 (7.9) volved in the susceptibility of individuals to PD in Jap-
125-B-R2 4 (3.9) 2 (5.3) anese, although the association between this haplotype127-B-R1 3 (2.9) 0 (0)
and the level of MAOA activity was not demonstrated127-B-R2 2 (2.0) 1 (2.6)
in our study.
Note. n: number of X chromosomes analyzed. These ®ndings support the hypothesis that the
* Signi®cant (p  0.005. Fisher's exact test.) MAOA gene may affect the susceptibility of individuals
to PD among MAOA polymorphic loci. In this sense,
we expect that more haplotypes of the MAOA locus
population using the same method described by Kurth will be discovered in patients with PD, and further
et al.. They found that no allelic association between investigation should be undertaken in a larger sample
size.patients and controls, and there was an ethnic differ-
TABLE 4
Distribution of Alleles at the MAOB Locus in Controls and Patients with Parkinson's Disease
Total Male Female
Control (N  196) Patients (N  68) Control (N  97) Patients (N  38) Control (N  99) Patients (N  30)
Allele n n n n n n
MAOB-GT
166 1 (0.3) 1 (1.0) 0 (0) 0 (0) 1 (0.5) 1 (1.7)
168 2 (0.7) 3 (3.1) 1 (1.0) 2 (5.3) 1 (0.5) 1 (1.7)
170 28 (9.5) 13 (13.3) 14 (14.4) 8 (21.1) 14 (7.1) 5 (8.3)
172 16 (5.4) 4 (4.1) 7 (7.2) 2 (5.3) 9 (4.5) 2 (3.3)
174 5 (1.7) 3 (3.1) 1 (1.0) 1 (2.6) 4 (2.0) 2 (3.3)
176 8 (2.7) 3 (3.1) 2 (2.1) 1 (2.6) 6 (3.0) 2 (3.3)
178 19 (6.4) 8 (8.2) 7 (7.2) 3 (7.9) 12 (6.1) 5 (8.3)
180 22 (7.5) 6 (6.1) 9 (9.3) 3 (7.9) 13 (6.6) 3 (5.0)
182 54 (18.3) 16 (16.3) 12 (12.4) 3 (7.9) 42 (21.2) 13 (21.7)
184 101 (34.2) 30 (30.6) 39 (40.2) 13 (34.2) 62 (31.3) 17 (28.3)
186 30 (10.2) 8 (8.2) 4 (4.1) 1 (2.6) 26 (13.1) 7 (11.7)
188 9 (3.1) 3 (3.1) 1 (1.0) 1 (2.6) 8 (4.0) 2 (3.3)
Note. Number in parentheses indicates percentage. N: number of individuals; n: number of X chromosomes analyzed.
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